Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: Journal of Medical Internet Research

Date Submitted: Aug 2, 2024
Date Accepted: Oct 9, 2024

The final, peer-reviewed published version of this preprint can be found here:

Smartphone App for Improving Self-Awareness of Adherence to Edoxaban Treatment in Patients With Atrial Fibrillation (ADHERE-App Trial): Randomized Controlled Trial

Yoon M, Lee JH, Kim IC, Lee JH, Kim M, Kim HL, Lee S, Kim IJ, Choi S, Park SJ, Hur T, Hussain M, Lee S, Choi DJ

Smartphone App for Improving Self-Awareness of Adherence to Edoxaban Treatment in Patients With Atrial Fibrillation (ADHERE-App Trial): Randomized Controlled Trial

J Med Internet Res 2024;26:e65010

DOI: 10.2196/65010

PMID: 39570659

PMCID: 11621717

Smartphone application for improving self-awareness of adherence to edoxaban treatment in atrial fibrillation (ADHERE-App trial): A randomized controlled trial

  • Minjae Yoon; 
  • Ji Hyun Lee; 
  • In-Cheol Kim; 
  • Ju-Hee Lee; 
  • Mina Kim; 
  • Hack-Lyoung Kim; 
  • Sunki Lee; 
  • In Jai Kim; 
  • Seonghoon Choi; 
  • Sung-Ji Park; 
  • Taeho Hur; 
  • Musarrat Hussain; 
  • Sungyoung Lee; 
  • Dong-Ju Choi

ABSTRACT

Background:

Adherence to oral anticoagulant therapy is essential to prevent stroke in patients with atrial fibrillation (AF).

Objective:

This study aimed to evaluate whether smartphone application-based interventions improve medication adherence in patients with AF.

Methods:

This randomized, open-label, multicenter trial enrolled patients with AF treated with edoxaban for stroke prevention. They were randomly assigned to application-conditioned feedback (intervention, n=248) and conventional treatment (control, n=250) groups. The intervention group daily received alerts via a smartphone application to take edoxaban and measure blood pressure and heart rate at specific times. The control group received only standard guideline-recommended care. The primary endpoint was edoxaban adherence, measured by pill count at 3 or 6 months. Medication adherence and proportion of adequate medication adherence, which was defined as ≥95% of continuous medication adherence, were evaluated.

Results:

Medication adherence at 3 or 6 months was not significantly different between the intervention and control groups (98.0% [95.0%–100.0%] vs. 98.0% [91.0%–100.0%] for 3 months, P=.06; 98.0% [94.5%–100.0%] vs. 97.5% [92.8%–100.0%] for 6 months, P=.15). However, the proportion of adequate medication adherence (≥95%) was significantly higher in the intervention group at both time points (76.8% vs. 64.7%, P=.01; 73.9% vs. 61.0%, P=.007). Among patients aged >65 years, the intervention group showed a higher medication adherence value and a higher proportion of adequate medication adherence (≥95%) at 6 months.

Conclusions:

There was no difference in edoxaban adherence between the groups. However, the proportion of adequate medication adherence was higher in the intervention group, and the benefit of the smartphone application-based intervention on medication adherence was more pronounced among older patients than among younger patients. Given the low adherence to oral anticoagulants, especially among older adults, using a smartphone application may potentially improve medication adherence. Clinical Trial: International Clinical Trials Registry Platform KCT0004754


 Citation

Please cite as:

Yoon M, Lee JH, Kim IC, Lee JH, Kim M, Kim HL, Lee S, Kim IJ, Choi S, Park SJ, Hur T, Hussain M, Lee S, Choi DJ

Smartphone App for Improving Self-Awareness of Adherence to Edoxaban Treatment in Patients With Atrial Fibrillation (ADHERE-App Trial): Randomized Controlled Trial

J Med Internet Res 2024;26:e65010

DOI: 10.2196/65010

PMID: 39570659

PMCID: 11621717

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.